Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Invested Capital (2016 - 2025)

Theravance Biopharma (TBPH) has disclosed Invested Capital for 13 consecutive years, with $296.7 million as the latest value for Q4 2025.

  • Quarterly Invested Capital rose 69.03% to $296.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $296.7 million through Dec 2025, up 69.03% year-over-year, with the annual reading at $296.7 million for FY2025, 69.03% up from the prior year.
  • Invested Capital for Q4 2025 was $296.7 million at Theravance Biopharma, up from $232.7 million in the prior quarter.
  • The five-year high for Invested Capital was $480.6 million in Q3 2022, with the low at -$361.6 million in Q1 2021.
  • Average Invested Capital over 5 years is $86.6 million, with a median of $199.3 million recorded in 2024.
  • The sharpest move saw Invested Capital crashed 128.93% in 2021, then skyrocketed 254.5% in 2022.
  • Over 5 years, Invested Capital stood at -$321.6 million in 2021, then surged by 237.36% to $441.8 million in 2022, then plummeted by 51.79% to $213.0 million in 2023, then decreased by 17.58% to $175.5 million in 2024, then surged by 69.03% to $296.7 million in 2025.
  • According to Business Quant data, Invested Capital over the past three periods came in at $296.7 million, $232.7 million, and $224.8 million for Q4 2025, Q3 2025, and Q2 2025 respectively.